Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132240) titled 'Bispecific Antibody Combined with a Novel BCL-2 Inhibitor for the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia' on Sept. 10.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Beijing Childrens Hospital,Capital Medical University
Condition:
Pediatric B-cell acute lymphoblastic leukemia
Intervention:
Healthy/non-malignant control group:None
The control group of pediatric B-ALL (treated with BCL-2 inhibitor / bispecific monoclonal antibody monotherapy):None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-30
Target Sample Size: Hea...